JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

485.23 2.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

468.71

Максимум

490.03

Ключови измерители
By Trading Economics
Приходи	-72M -114M
Продажби	74M 287M
Марж на печалбата	-39.75
Служители	528
EBITDA	-68M -106M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+47.73% upside

Дивиденти
By Dow Jones
Следващи печалби	19.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.9B 11B
Предишно отваряне	482.97
Предишно затваряне	485.23

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.02.2026 г., 17:25 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Possible Technical Correction -- Market Talk

9.02.2026 г., 23:14 ч. UTC

Пазарно говорене

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9.02.2026 г., 22:29 ч. UTC

Пазарно говорене

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9.02.2026 г., 22:19 ч. UTC

Пазарно говорене

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9.02.2026 г., 22:01 ч. UTC

Печалби

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9.02.2026 г., 21:59 ч. UTC

Печалби

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9.02.2026 г., 21:58 ч. UTC

Печалби

Friedman Industries 3Q Sales $168M >FRD

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 21:48 ч. UTC

Печалби

Friedman Industries 3Q EPS 43c >FRD

9.02.2026 г., 21:17 ч. UTC

Печалби

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9.02.2026 г., 21:13 ч. UTC

Пазарно говорене

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9.02.2026 г., 21:04 ч. UTC

Печалби

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9.02.2026 г., 20:30 ч. UTC

Пазарно говорене

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9.02.2026 г., 20:02 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9.02.2026 г., 19:42 ч. UTC

Пазарно говорене

Japan's Yield Curve Expected to Flatten -- Market Talk

9.02.2026 г., 19:31 ч. UTC

Пазарно говорене

Nike Seen Regaining Relevance With Consumers -- Market Talk

9.02.2026 г., 19:27 ч. UTC

Пазарно говорене

Gold Climbs Back Over $5,000/oz -- Market Talk

9.02.2026 г., 19:05 ч. UTC

Пазарно говорене

Nike Returns to List of Hottest Brands -- Market Talk

9.02.2026 г., 18:19 ч. UTC

Пазарно говорене

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9.02.2026 г., 17:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9.02.2026 г., 17:31 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

9.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.02.2026 г., 17:17 ч. UTC

Пазарно говорене

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9.02.2026 г., 17:16 ч. UTC

Печалби

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

47.73% нагоре

12-месечна прогноза

Среден 705.56 USD 47.73%

Висок 964 USD

Нисък 570 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.